Diluted Humalog U-200 Insulin
Phase 1Small molecule
Diluted Humalog U-200 Insulin is one of 24 small molecule programs targeting Type 1 Diabetes. It is currently in Phase 1.
2
Indications
1
Total Trials
0
Active Trials
23
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
384 competitors in Type 1 Diabetes
#DrugCompanyPhaseTrials
1Symlin
AstraZenecaPreclinical
Symlin
AstraZenecaPreclinical
Aldomet
Neurocrine BiosciencesPreclinical
Glargine
Eli LillyPreclinical
Pitocin
RRetrophin
Preclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
Foradil
ViatrisPreclinical
SGLT2 Inhibitor
Eli LillyPreclinical
Teplizumab
SanofiPreclinical
Mesenchymal Stem Cells
JJiangsu Topcel-KH Pharmaceutical Co., Ltd.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- SStanford University